Skip to main content

Advertisement

SpringerLink
Log in

Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Today, using nanoparticle-based drug delivery systems has expanded to avoid anticancer side effects. Taxanes are important chemotherapeutic agents in the treatment of metastatic breast cancer. In this study, docetaxel (DTX)-loaded human serum albumin (HSA) nanoparticles (NPs) were prepared and characterized. Drug toxicity of the nanoparticles was measured by MTT assay with different drug concentrations (0.01, 0.1, 0.5, 1 and 5 μM) at different incubation times (24, 48 and 72 h). Expression of BAX/BCL2 mRNA levels was determined by real-time PCR. The size of NPs prepared and used in our study was about 147 nm with surface charge of −29.6 mV. Results obtained from MTT assay showed that 0.5 μM of free drug had 50 % toxicity on MCF-7 cells after 48-h incubation. Real-time PCR results showed an increase in expression of BAX and no change for BCL2. In conclusion, a significant overexpression of BAX gene and changes in BAX/BCL2 ratio were observed for DTX-loaded HSA nanoparticles compared with free DTX and may provide a potential therapy to inhibit anticancer drug resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Taghavi A, Fazeli Z, Vahedi M, Baghestani A, Pourheseingholi A, Barzegar F, Pourheseingholi M. Increased trend of breast cancer mortality in iran. APJCP. 2012;13(1):367–70.

    PubMed  Google Scholar 

  2. Fridman A, Chirokov A, Gutsol A. Non-thermal atmospheric pressure discharges. Phys. 2005;38:R1–24.

    CAS  Google Scholar 

  3. Zumoff B. Adjuvant treatment in breast cancer. Lancet. 1992;339:423–4.

    Article  CAS  PubMed  Google Scholar 

  4. Smith G, Henderson IC. New treatments for breast cancer. Semin Oncol. 1996;23:506–28.

    CAS  PubMed  Google Scholar 

  5. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997;57:229–33.

    CAS  PubMed  Google Scholar 

  6. Gumerlock P, Mack P, Gustafsson M, Togonon M, Gandara D. p27 induction as a potential p53-independent mechanism of apoptotic response to docetaxel in non-small cell lung (NSCL) and prostate carcinomas (CaP). Clin Cancer Res. 1999;5:s3859.

    Google Scholar 

  7. Herbst RS, Khuri FR. Mode of action of docetaxel a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003;29:407–15.

    Article  CAS  PubMed  Google Scholar 

  8. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anti-Cancer Drugs. 1995;6:339–55.

    Article  CAS  PubMed  Google Scholar 

  9. Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev. 1996;21:107–16.

    Article  CAS  Google Scholar 

  10. Panday VRN, Huizing MT, Huinink WWTB, Vermorken JB, Beijnen JH. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest. 1997;14:418–27.

    Article  CAS  Google Scholar 

  11. Riley T, Stolnik S, Heald CR, Xiong CD, Garnett MC, Illum L, Davis SS. Physicochemical evaluation of nanoparticles assembled from poly (lactic acid)-poly (ethylene glycol) (PLA-PEG) block copolymers as drug delivery vehicles. Langmuir. 2001;17:3168–74.

    Article  CAS  Google Scholar 

  12. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science. 2003;300:615–8.

    Article  CAS  PubMed  Google Scholar 

  13. Deim K. Synopsis of plasma proteins scientific tables, vol. 6. DocumentaGeigy: Geigy Pharmaceuticals, Ardsley; 1962.

    Google Scholar 

  14. Sebak S, Mirzaei M, Malhorta M, Kulamarva A, Prakash S. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomed. 2010;5:525–32.

    CAS  Google Scholar 

  15. Kratz F, Muller DR, Hofmann I, Drevs J, Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem. 2000;43:1253–6.

    Article  CAS  PubMed  Google Scholar 

  16. Giannoukakis N. Current opinion in investigational drugs (London, England: 2000). CJC-1131. 2003;4:1245–9.

  17. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, Green DR. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci. 2008;105:20327–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59.

    Article  CAS  PubMed  Google Scholar 

  19. Walensky LD, Gavathiotis E. BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci. 2011;36:642–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37:299–310.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med. 2014;65:139–55.

    Article  CAS  PubMed  Google Scholar 

  22. Green DR, Beere H, Hickman JA, Dive C. Apoptosis and cancer chemotherapy: mechanisms of apoptosis. New Jersey: Humana Press; 1999. p. 157–74.

    Book  Google Scholar 

  23. Siervo-Sassi RR, Marrangoni A, Feng X, Naoumova N, Winans M, Edwards RP, Lokshin A. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett. 2003;190:61–72.

    Article  CAS  PubMed  Google Scholar 

  24. Thomadaki H, Scorilas A. Breast cancer cells response to the antineoplastic agentscisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007;1095:35–44.

    Article  CAS  PubMed  Google Scholar 

  25. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157:168–82.

    Article  CAS  PubMed  Google Scholar 

  26. Chen W, Gu B, Wang H, Pan J, Lu W, Hou H. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm. 2008;362:133–40.

    Article  CAS  PubMed  Google Scholar 

  27. Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, Maier-Borst W, Heene DL. Plasma protein (albumin) catabolism by the tumor itself—implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26:77–100.

    Article  CAS  PubMed  Google Scholar 

  28. John TA, Vogel S, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol. 2003;284:L187–96.

    Article  CAS  PubMed  Google Scholar 

  29. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317–24.

    Article  CAS  PubMed  Google Scholar 

  30. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30:592–9.

    Article  CAS  PubMed  Google Scholar 

  31. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanoedicine. 2009;4:99–105.

    CAS  Google Scholar 

  32. Chew L, Chuen V. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract. 2009;15:29–34.

    Article  CAS  PubMed  Google Scholar 

  33. Akay BN, Unlu E, Buyukcelik A, Akyol A. Photosensitive rash in associationwithporphyrin biosynthesis possibly induced by docetaxel andtrastuzumab therapy in a patient with metastatic breast carcinoma. Jpn J Clin Oncol. 2010;40:989–91.

    Article  PubMed  Google Scholar 

  34. Manoochehri S, Darvish B, Kamalinia G, Amini M, Fallah M, Ostad SN, Atyabi F, Dinarvand R. Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. Daru J Pharm Sci. 2013;21:58.

    Article  CAS  Google Scholar 

  35. John TA, Vogel S, Minshall RD, Ridge K, Tiruppathi C, Malik AB. Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung. J Physol. 2001;533:547–59.

    Article  CAS  Google Scholar 

  36. Fritzsche T, Schnolzer M, Fiedler S, Weigand M, Wiessler M, Frei E. Isolation and identification of heterogeneous nuclear ribonucleoproteins (hnRNP) from purified plasma membranes of human tumour cell lines as albumin-binding proteins. Biochem Pharmacol. 2004;67:655–65.

    Article  CAS  PubMed  Google Scholar 

  37. Van Sluis R, Bhujwalla Z, Raghunand N, Ballesteros P, Alvarez J, Cerdan S, Galons J-P, Gillies RJ. In vivo imaging of extracellular pH using 1 H MRSI. Magn Reson Med. 1999;41:743–50.

    Article  PubMed  Google Scholar 

  38. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+ /H+ exchanger in metastasis. Nat Rev Cancer. 2005;5:786–95.

    Article  CAS  PubMed  Google Scholar 

  39. Kanani N, Neumann E, Frei E, Funk D, Becker MD, Schrenk H-H, Müller-Ladner U, Fiehn C. Electroplating-basic principles processes native albumin for targeted drug delivery. Expert Opn Drug Deiv. 2010;7:915–25.

    Article  Google Scholar 

  40. Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells. 1998;3:697–707.

    Article  CAS  PubMed  Google Scholar 

  41. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 2003;39:615–47.

    Article  CAS  PubMed  Google Scholar 

  42. Kraus LA, Samuel SK, Schmid SM, Dykes DJ. The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation. Invest New Drugs. 2003;21:259–68.

    Article  CAS  PubMed  Google Scholar 

  43. Nizar MM, Yufang W, Kelly AK, Xu DZ, Peter H. Dcoetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol Cancer Ther. 2007;6:752–61.

    Article  Google Scholar 

  44. Lo YL. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol. 2000;60:1381–90.

    Article  CAS  PubMed  Google Scholar 

  45. Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release. 2003;93:151–60.

    Article  CAS  PubMed  Google Scholar 

  46. Honma K, Iwao KK, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K, Ochiya T. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med. 2008;14:939–48.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Biology, School of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran

    Marzieh Kordezangeneh & Shiva Irani

  2. Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Reza Mirfakhraie

  3. Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, Iran

    Mehdi Esfandyari-Manesh, Fatemeh Atyabi & Rassoul Dinarvand

  4. Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Fatemeh Atyabi & Rassoul Dinarvand

Authors
  1. Marzieh Kordezangeneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiva Irani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reza Mirfakhraie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehdi Esfandyari-Manesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fatemeh Atyabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rassoul Dinarvand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Shiva Irani or Rassoul Dinarvand.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kordezangeneh, M., Irani, S., Mirfakhraie, R. et al. Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles. Med Oncol 32, 208 (2015). https://doi.org/10.1007/s12032-015-0652-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-015-0652-5

Keywords

Search

Navigation